IDEXX LABORATORIES INC /DE (IDXX) Form 8-K — Nov 2, 2026
IDEXX Laboratories (NASDAQ: IDXX) announced Q3 2026 results with revenue of $1,214 million, up 10% as reported and organic, and diluted EPS of $4.01, up 18% as reported and 22% on a comparable basis. CAG Diagnostics recurring revenue grew 11%, powered by 14% organic growth in VetLab consumables and double-digit international expansion, while the company placed over 1,900 IDEXX inVue Dx analyzers to reach a nearly 11,000-instrument installed base.
Key figures
- Eps
- 4.01
- Revenue
- 1214237000
- Guidance
- FY2026 revenue $4,741M-$4,767M (raised $32M at midpoint), EPS $14.96-$15.16 (raised $0.25 at midpoint), organic revenue growth 9.3%-10.0%, operating margin 32.1%-32.3%
- Net Income
- 317145000
- Revenue Yoy
- 10% reported and organic
- Total Assets
- 3707109000
- Cash Position
- 197536000
- Shares Outstanding
- 78825000
- Q3 2025 eps
- 3.4
- Gross margin
- 62.9% (+110 bps)
- Q3 2025 revenue
- 1105239000
- Operating margin
- 33.1% (+100 bps)
- Q3 free cash flow
- 420787000
- Invue dx placements
- over 1,900 (installed base near 11,000)
- Q3 open market buybacks usd
- 111819000
- Cag diagnostics recurring growth
- 11% reported and organic
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.